Literature DB >> 15983304

Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes.

Erika J Sims1, Michael W Green, Anil Mehta.   

Abstract

OBJECTIVE: Although cystic fibrosis-related diabetes (CFRD) is associated with decreased lung function, sex is not known to influence CFRD. However, compared with male subjects with cystic fibrosis, female subjects with cystic fibrosis have increased morbidity. This study examines the association between female subjects with CFRD and poor lung function relative to male subjects using the percent predicted forced expiratory volume in 1 s (FEV(1)) as a surrogate measure of morbidity. RESEARCH DESIGN AND METHODS: We compared 323 patients with established CFRD with 489 cystic fibrosis control subjects with normal glucose tolerance (NGT) listed in the U.K. Cystic Fibrosis Database. Patients stratified by sex and chronic Pseudomonas aeruginosa infection were compared using binary logistic regression, and patients with new CFRD diagnoses were compared prospectively for the year 2002.
RESULTS: CFRD in female subjects (but not male subjects) without chronic P. aeruginosa infection had a 20% lower percent predicted FEV(1) compared with control subjects with NGT (95% CI -11.7 to -27.7; P < 0.0001). Genotype, age, treatment center, age at diagnosis of cystic fibrosis, pregnancy, liver function, or dose of pancreatic enzyme replacement therapy did not confound this female disadvantage. Comparison of female subjects with newly diagnosed CFRD free of chronic P. aeruginosa infection with matched control subjects with NGT showed no FEV(1) disadvantage in the 1st year after CFRD diagnosis.
CONCLUSIONS: Only female subjects with CFRD have significantly decreased lung function compared with sex-matched NGT control subjects. The absence of poor lung function in the first 12 months after diagnosis of diabetes suggests that an opportunity may exist to intervene and possibly prevent a decline in lung function, which can be as much as 20% in female subjects with CFRD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983304     DOI: 10.2337/diacare.28.7.1581

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  20 in total

Review 1.  Routine screening for cystic fibrosis-related diabetes.

Authors:  Daniel Peckham
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

2.  Gonadal hormones and oxidative stress interaction differentially affects survival of male and female mice after lung Klebsiella pneumoniae infection.

Authors:  Faryal Durrani; David S Phelps; Judith Weisz; Patricia Silveyra; Sanmei Hu; Anatoly N Mikerov; Joanna Floros
Journal:  Exp Lung Res       Date:  2012-03-06       Impact factor: 2.459

3.  Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex.

Authors:  Connor Lewis; Scott M Blackman; Amanda Nelson; Ewa Oberdorfer; Daniel Wells; Jordan Dunitz; William Thomas; Antoinette Moran
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

4.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

5.  Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study.

Authors:  R J Miller; H D Tildesley; P G Wilcox; H Zhang; S H Kreisman
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

Review 6.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

7.  Sex differences in the expression of lung inflammatory mediators in response to ozone.

Authors:  Noe Cabello; Vikas Mishra; Utkarshna Sinha; Susan L DiAngelo; Zissis C Chroneos; Ndifreke A Ekpa; Timothy K Cooper; Carla R Caruso; Patricia Silveyra
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-04       Impact factor: 5.464

8.  Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.

Authors:  Angel Li; Tim Vigers; Laura Pyle; Edith Zemanick; Kristen Nadeau; Scott D Sagel; Christine L Chan
Journal:  J Cyst Fibros       Date:  2018-08-10       Impact factor: 5.482

9.  Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Authors:  Antoinette Moran; Carol Brunzell; Richard C Cohen; Marcia Katz; Bruce C Marshall; Gary Onady; Karen A Robinson; Kathryn A Sabadosa; Arlene Stecenko; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

10.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.